[go: up one dir, main page]

JP4644391B2 - Skin preparation - Google Patents

Skin preparation Download PDF

Info

Publication number
JP4644391B2
JP4644391B2 JP2001197282A JP2001197282A JP4644391B2 JP 4644391 B2 JP4644391 B2 JP 4644391B2 JP 2001197282 A JP2001197282 A JP 2001197282A JP 2001197282 A JP2001197282 A JP 2001197282A JP 4644391 B2 JP4644391 B2 JP 4644391B2
Authority
JP
Japan
Prior art keywords
skin
ceramide
acid
external preparation
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001197282A
Other languages
Japanese (ja)
Other versions
JP2003012486A (en
Inventor
泰三 関
速 前田
泰之 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP2001197282A priority Critical patent/JP4644391B2/en
Publication of JP2003012486A publication Critical patent/JP2003012486A/en
Application granted granted Critical
Publication of JP4644391B2 publication Critical patent/JP4644391B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、皮膚のバリア機能を向上させ、優れた皮膚保湿効果及び皮膚保護効果を発揮し、小じわやきめの粗さといった皮膚の老化症状を予防,改善し得る皮膚外用剤に関する。さらに詳しくは、II型セラミド及びIII型セラミドの混合物を、炭素数16〜18の分岐鎖を有する脂肪酸,炭素数10〜24の分岐鎖を有する脂肪族アルコール,グリセリルモノオレイルエーテルより選択した1種又は2種以上とともに含有して成る皮膚外用剤に関する。
【0002】
【従来の技術】
乾燥,紫外線等種々の環境因子や、加齢に伴う皮膚の老化、アトピー性病変等により、皮膚角質層のバリアー機能が低下し、肌荒れ症状が生じることが知られており、皮膚角質層のバリアー機能に関与するセラミドを配合した皮膚外用剤が数多く開示されている。
【0003】
皮膚角質層のバリアー機能を構築するには、セラミドがラメラ状に配列される必要があるが、動物組織より抽出したセラミド混合物を単に皮膚外用剤に配合しただけでは、かかる配列を得ることはできない。また、皮膚のセラミドと同一の立体異性体構造を有するIII型セラミドの製法が知られているが、III型セラミドは融点が高く、皮膚外用剤基剤に溶解することが困難である。
【0004】
III型セラミドの融点を低下させる試みとしては、V型セラミドと併用する技術が知られている(特開平8−225427)。しかしながら、より安定な皮膚外用剤を得るには、皮膚外用剤基剤に対するセラミドの溶解性を向上させる必要があり、皮膚角質層のバリアー機能を向上させるためには、セラミドの経皮吸収性を向上させる必要があった。
【0005】
【発明が解決しようとする課題】
そこで本発明においては、セラミドの溶解性が良好で製剤安定性に優れ、さらにセラミドの経皮吸収も良好で、皮膚角質層バリアー機能を有効に向上させることができ、優れた皮膚の保湿効果及び保護効果を発揮し得る皮膚外用剤を得ることを目的とした。
【0006】
【課題を解決するための手段】
上記課題を解決するべく種々検討した結果、II型セラミド及びIII型セラミドの混合物を、炭素数16〜18の分岐鎖を有する脂肪酸,炭素数10〜24の分岐鎖を有する脂肪族アルコール,グリセリルモノオレイルエーテルより選択した1種又は2種以上とともに含有させることにより、皮膚外用剤基剤に対する溶解性及び経皮吸収性が向上し、優れた皮膚の保湿効果及び保護効果が得られ、その結果、小じわやきめの粗さといった皮膚の老化症状の予防,改善にも有効であることを見いだし、本発明を完成するに至った。
【0007】
【発明の実施の形態】
本発明において用いるII型セラミドは、N-アシルスフィンゴシン又はN-アシルジヒドロスフィンゴシンであり、動物等の各組織より抽出,分画して得たものや、化学的もしくは酵素的手法により合成されたものを用いることができる。アシル基としては、炭素数12〜38程度の飽和又は不飽和のものが好ましく、ヒドロキシル基を有するものでもよい。
【0008】
また、本発明においてII型セラミドとともに用いるIII型セラミドは、N-アシルフィトスフィンゴシンであり、動物,植物,酵母等の各組織より抽出,分画して得たものや、化学的もしくは酵素的手法により合成されたものを用いることができる。アシル基としては、炭素数12〜38程度の飽和又は不飽和のものが好ましく、ヒドロキシル基を有するものでもよい。
【0009】
本発明において用いるII型セラミドとIII型セラミドとの混合物におけるこれら各セラミドの混合重量比としては、4:6〜6:4の範囲とするのが適切である。
【0010】
本発明において、II型セラミド及びIII型セラミドの混合物と併用する炭素数16〜18の分岐鎖を有する脂肪酸としては、分岐鎖を有する飽和脂肪酸が好ましく、14-メチルペンタデカン酸,16-メチルヘプタデカン酸,2-ヘプチルウンデカン酸及び式(1)で示される2-イソヘプチルイソウンデカン酸が好ましいものとして例示され、本発明においてはこれらより1種又は2種以上を選択して用いる。特に、常温で液状を呈するものが好ましく用いられる。
【化3】

Figure 0004644391
【0011】
また本発明において、II型セラミド及びIII型セラミドの混合物と併用する炭素数10〜24の分岐鎖を有する脂肪族アルコールとしては、分岐鎖を有する飽和の脂肪族アルコールが好ましく、常温で液状を呈するものが特に好ましく用いられる。式(2)で示される脂肪族アルコール,2-ヘキシルデカノール,2-オクチルドデカノール,2-デシルテトラデカノール等が好ましいものとして例示され、これらより1種又は2種以上を選択して用いる。
【化4】
Figure 0004644391
【0012】
さらに本発明においては、II型セラミド及びIII型セラミドの混合物と、常温で液状を呈するグリセリルモノオレイルエーテル(セラキルアルコール)とを併用することができる。
【0013】
本発明におけるII型セラミド及びIII型セラミドの混合物と、炭素数16〜18の分岐鎖を有する脂肪酸,炭素数10〜24の分岐鎖を有する脂肪族アルコール,グリセリルモノオレイルエーテルより選択した1種又は2種以上との混合重量比としては、0.01:100〜1:1の範囲とするのが適切である。また、本発明に係る皮膚外用剤全量に対するII型セラミド及びIII型セラミドの混合物、及び炭素数16〜18の分岐鎖を有する脂肪酸,炭素数10〜24の分岐鎖を有する脂肪族アルコール,グリセリルモノオレイルエーテルより選択した1種又は2種以上の含有量としては、それぞれ0.00001〜10.0重量%及び0.1〜20.0重量%とするのが適切であり、さらに好ましくは、0.0001〜5.0重量%及び0.5〜10.0重量%とする。
【0014】
本発明に係る皮膚外用剤は、ローション剤,乳剤,ゲル剤,クリーム剤,軟膏剤等の形状で提供することができる。また、化粧水,乳液,ゲル,クリーム,パック等の皮膚化粧料、液状もしくはクリーム状の下地化粧料、液状,クリーム状もしくは油性タイプのファンデーション,アイカラー,チークカラー等のメイクアップ化粧料、ハンドローション,ハンドクリーム,レッグクリーム,ネッククリーム,ボディローション等の身体用化粧料、クレンジングローション,クレンジングクリーム,クレンジングフォーム等の洗顔料、ボディソープ等の身体用洗浄料、ヘアーシャンプー,ヘアーリンス,ヘアーコンディショナー,ヘアークリーム等の毛髪用化粧料などとして提供され得る。
【0015】
なお、本発明に係る皮膚外用剤には、セラミド混合物の溶解性に影響を与えない範囲で、動植物性油脂類,ロウ類,脂肪酸,脂肪族アルコール,エステル油類,炭化水素油類といった他の油性成分、界面活性剤、エタノール等の低級アルコール、多価アルコール,ピロリドンカルボン酸塩,ムコ多糖類等の保湿剤、乳酸及びその塩,クエン酸及びその塩等のpH調整剤、水酸化カリウム,水酸化ナトリウム,L-アルギニン等の塩基類、酵母抽出物,シルク加水分解物等の細胞賦活剤、アスコルビン酸誘導体等の美白剤、トコフェロール及びその誘導体等の抗酸化剤、アラントイン,グリチルレチン酸及びその誘導体等の抗炎症剤、紫外線防止剤、防菌防黴剤、香料、色素、顔料、海藻抽出物、各種植物抽出物等、皮膚外用剤に一般的に配合される成分を含有させることができる。
【0016】
【実施例】
さらに本発明の特徴について、実施例により詳細に説明する。
【0017】
[実施例1,実施例2] 保湿クリーム
表1に示す処方中、Aの水相成分を混合,加熱溶解して80〜85℃とする。一方、C成分を混合,加熱溶解して80〜85℃とし、これにあらかじめ混合,加熱溶解して80〜85℃としたB成分を加えて均一とする。この油相成分に前記水相成分を撹拌しながら徐々に添加して均一に乳化し、冷却後50℃にてD成分を加え、さらに35℃まで冷却する。
【0018】
【表1】
Figure 0004644391
【0019】
[実施例3,実施例4] 保湿ジェル
表2に示す処方中、Aの水相成分を混合,加熱溶解して80〜85℃とする。一方、C成分を混合,加熱溶解して80〜85℃とし、これにあらかじめ混合,加熱溶解して80〜85℃としたB成分を加えて均一とする。この油相成分に前記水相成分を撹拌しながら徐々に添加して均一に乳化し、冷却後50℃にてD成分を加え、さらに35℃まで冷却する。
【0020】
【表2】
Figure 0004644391
【0021】
[実施例5,実施例6] 保湿乳液
表3に示す処方中、Aの水相成分を混合,加熱溶解して80〜85℃とする。一方、C成分を混合,加熱溶解して80〜85℃とし、これにあらかじめ混合,加熱溶解して80〜85℃としたB成分を加えて均一とする。この油相成分に前記水相成分を撹拌しながら徐々に添加して均一に乳化し、冷却後50℃にてD成分及びE成分を加え、さらに35℃まで冷却する。
【0022】
【表3】
Figure 0004644391
【0023】
[実施例7,実施例8] 保湿ゲル
表4に示す処方中、A成分を混合,溶解して80〜85℃とする。これに、あらかじめ混合,加熱溶解して80〜85℃としたB成分及びC成分を加えて混合,均一化し、冷却する。次いでこれにD成分を混合して徐々に添加し、撹拌混合してゲルを形成させた後、E成分を添加,混合する。
【0024】
【表4】
Figure 0004644391
【0025】
上記本発明の実施例について、製剤安定性,皮膚保湿効果及び皮膚保護効果の評価を行った。その際、各実施例において表5に示すように含有成分の代替を行ってそれぞれ比較例1〜比較例8とし、同時に試験に供した。
【0026】
【表5】
Figure 0004644391
【0027】
製剤安定性については、実施例及び比較例のそれぞれを25℃で6カ月間保存し、含有成分の析出,分離,凝集、相分離といった状態変化の有無を観察し、これらの状態変化が全く見られなかった場合を○、若干見られた場合を△、顕著に見られた場合を×として表した。また、皮膚保湿効果及び皮膚保護効果は、顕著な肌荒れ症状を呈する女性パネラー20名を1群とした使用試験を行って評価した。すなわち、実施例及び比較例をそれぞれ各群にブラインドにて1日2回、2カ月間使用させ、使用試験開始前及び使用試験終了後の角質層水分量の測定及び皮膚状態の観察を行った。角質層水分量は、皮表の高周波電気伝導度(コンダクタンス)を測定し、皮膚表面のコンダクタンス値にて表した。一方皮膚の状態は、表6に示す評価基準に従って評価,点数化し、20名の平均値を算出して示した。これらの結果は、表7にまとめて示した。
【0028】
【表6】
Figure 0004644391
【0029】
【表7】
Figure 0004644391
【0030】
表7より明らかなように、本発明の実施例はすべて良好な製剤安定性を示しており、使用試験においても、全群で皮膚角質層水分量の明らかな向上が認められ、皮膚の状態もほぼ良好な状態にまで改善されていた。
【0031】
これに対し、N-ステアロイルフィトスフィンゴシンをスクワランに代替した比較例4、及びN-パルミトイルフィトスフィンゴシンを16-メチルヘプタデカン酸に代替した比較例7以外においては、製剤安定性の低下が認められていた。また、使用試験終了後の皮膚角質層水分量及び皮膚の状態は、比較例使用群においても向上及び改善が見られてはいたが、その程度はそれぞれ対応する実施例使用群に比べて小さくなっていた。
【0032】
なお、本発明の実施例1〜実施例8については、男性パネラー30名を1群とした48時間の背部閉塞貼付試験においても、問題となる皮膚刺激性反応は見られなかった。
【0033】
【発明の効果】
以上詳述したように、本発明により、セラミドの溶解性が良好で製剤安定性に優れ、さらにセラミドの経皮吸収も良好で、皮膚角質層バリアー機能を有効に向上させることができ、優れた皮膚の保湿効果及び保護効果を発揮し得る皮膚外用剤を得ることができた。
【0034】
従って、本発明に係る皮膚外用剤を使用することにより、小じわや皮膚のきめの粗さといった皮膚の老化症状を有効に予防,改善することができる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a skin external preparation that improves skin barrier function, exhibits an excellent skin moisturizing effect and skin protecting effect, and can prevent and improve skin aging symptoms such as fine lines and texture. More specifically, a mixture of type II ceramide and type III ceramide is selected from fatty acids having a branched chain having 16 to 18 carbon atoms, aliphatic alcohols having a branched chain having 10 to 24 carbon atoms, and glyceryl monooleyl ether. Or it is related with the skin external preparation comprised with 2 or more types.
[0002]
[Prior art]
It is known that the skin function of the skin stratum corneum decreases due to various environmental factors such as dryness and ultraviolet rays, aging of the skin with age, atopic lesions, etc., resulting in rough skin. Many external preparations for skin containing ceramides involved in function have been disclosed.
[0003]
In order to construct the barrier function of the skin stratum corneum, ceramides must be arranged in a lamellar form, but such a sequence cannot be obtained simply by blending a ceramide mixture extracted from animal tissue into a skin external preparation. . In addition, a method for producing a type III ceramide having the same stereoisomeric structure as ceramide in skin is known, but type III ceramide has a high melting point and is difficult to dissolve in a skin external preparation base.
[0004]
As an attempt to lower the melting point of type III ceramide, a technique used in combination with V type ceramide is known (Japanese Patent Laid-Open No. 8-225427). However, in order to obtain a more stable external preparation for skin, it is necessary to improve the solubility of ceramide in the base for external preparation for skin. In order to improve the barrier function of the skin stratum corneum, the percutaneous absorption of ceramide must be improved. There was a need to improve.
[0005]
[Problems to be solved by the invention]
Therefore, in the present invention, the solubility of ceramide is good, the preparation stability is excellent, and the percutaneous absorption of ceramide is also good, the skin stratum corneum barrier function can be effectively improved, and the excellent skin moisturizing effect and The object was to obtain a skin external preparation capable of exhibiting a protective effect.
[0006]
[Means for Solving the Problems]
As a result of various studies to solve the above-mentioned problems, a mixture of type II ceramide and type III ceramide was converted into a fatty acid having a branched chain having 16 to 18 carbon atoms, an aliphatic alcohol having a branched chain having 10 to 24 carbon atoms, and glyceryl mono By including together with one or more selected from oleyl ether, the solubility and transdermal absorbability to the skin external preparation base are improved, and an excellent skin moisturizing effect and protective effect are obtained. The inventors have found that the present invention is effective in preventing and improving skin aging symptoms such as fine wrinkles and graininess, and have completed the present invention.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
The type II ceramide used in the present invention is N-acyl sphingosine or N-acyl dihydrosphingosine, which is obtained by extraction and fractionation from various tissues such as animals, or synthesized by chemical or enzymatic methods. Can be used. The acyl group is preferably a saturated or unsaturated group having about 12 to 38 carbon atoms, and may have a hydroxyl group.
[0008]
In addition, the type III ceramide used together with the type II ceramide in the present invention is N-acylphytosphingosine, which is obtained by extraction and fractionation from tissues such as animals, plants and yeasts, and chemical or enzymatic methods. The one synthesized by can be used. The acyl group is preferably a saturated or unsaturated group having about 12 to 38 carbon atoms, and may have a hydroxyl group.
[0009]
The mixing weight ratio of these ceramides in the mixture of type II ceramide and type III ceramide used in the present invention is suitably in the range of 4: 6 to 6: 4.
[0010]
In the present invention, the fatty acid having a branched chain having 16 to 18 carbon atoms used in combination with a mixture of type II ceramide and type III ceramide is preferably a saturated fatty acid having a branched chain, such as 14-methylpentadecanoic acid and 16-methylheptadecane. Acid, 2-heptylundecanoic acid and 2-isoheptylisoundecanoic acid represented by the formula (1) are exemplified as preferred ones. In the present invention, one or more of these are selected and used. In particular, those that are liquid at room temperature are preferably used.
[Chemical 3]
Figure 0004644391
[0011]
In the present invention, the aliphatic alcohol having a branched chain having 10 to 24 carbon atoms to be used in combination with a mixture of type II ceramide and type III ceramide is preferably a saturated aliphatic alcohol having a branched chain, and exhibits a liquid state at room temperature. Those are particularly preferably used. Aliphatic alcohols represented by the formula (2), 2-hexyldecanol, 2-octyldodecanol, 2-decyltetradecanol and the like are exemplified as preferred ones, and one or more of these are selected and used.
[Formula 4]
Figure 0004644391
[0012]
Furthermore, in the present invention, a mixture of type II ceramide and type III ceramide can be used in combination with glyceryl monooleyl ether (ceracyl alcohol) that is liquid at room temperature.
[0013]
A mixture of type II ceramide and type III ceramide in the present invention, a fatty acid having a branched chain having 16 to 18 carbon atoms, an aliphatic alcohol having a branched chain having 10 to 24 carbon atoms, or glyceryl monooleyl ether or The mixing weight ratio with two or more is suitably in the range of 0.01: 100 to 1: 1. Further, a mixture of type II ceramide and type III ceramide with respect to the total amount of the external preparation for skin according to the present invention, a fatty acid having a branched chain having 16 to 18 carbon atoms, an aliphatic alcohol having a branched chain having 10 to 24 carbon atoms, and glyceryl mono The content of one or more selected from oleyl ether is suitably 0.00001 to 10.0% by weight and 0.1 to 20.0% by weight, respectively, more preferably 0 0.0001 to 5.0% by weight and 0.5 to 10.0% by weight.
[0014]
The external preparation for skin according to the present invention can be provided in the form of a lotion, emulsion, gel, cream, ointment and the like. Also, skin cosmetics such as lotion, milky lotion, gel, cream, pack, liquid or cream base cosmetic, makeup cosmetics such as liquid, cream or oil type foundation, eye color, teak color, hand, etc. Body cosmetics such as lotions, hand creams, leg creams, neck creams, body lotions, cleansing lotions, cleansing creams, cleansing foams, body cleans such as body soaps, hair shampoos, hair rinses, hair conditioners , And can be provided as a cosmetic for hair such as a hair cream.
[0015]
The external preparation for skin according to the present invention has other effects such as animal and vegetable oils and fats, waxes, fatty acids, aliphatic alcohols, ester oils and hydrocarbon oils, as long as the solubility of the ceramide mixture is not affected. Oil components, surfactants, lower alcohols such as ethanol, polyhydric alcohols, pyrrolidone carboxylates, mucopolysaccharides and other moisturizers, lactic acid and salts thereof, pH adjusters such as citric acid and salts thereof, potassium hydroxide, Bases such as sodium hydroxide and L-arginine, cell activators such as yeast extract and silk hydrolysate, whitening agents such as ascorbic acid derivatives, antioxidants such as tocopherol and its derivatives, allantoin, glycyrrhetinic acid and its Commonly used in skin preparations such as derivatives such as anti-inflammatory agents, UV inhibitors, antifungal agents, perfumes, pigments, pigments, seaweed extracts, various plant extracts, etc. Component may be contained that.
[0016]
【Example】
Further, the features of the present invention will be described in detail with reference to examples.
[0017]
[Example 1 and Example 2] Moisturizing cream In the formulation shown in Table 1, the water phase component of A is mixed, heated and dissolved to 80 to 85 ° C. On the other hand, the C component is mixed and dissolved by heating to 80 to 85 ° C., and the B component which is mixed and heated and dissolved in advance to 80 to 85 ° C. is added to be uniform. The aqueous phase component is gradually added to the oil phase component while stirring to uniformly emulsify, and after cooling, the D component is added at 50 ° C. and further cooled to 35 ° C.
[0018]
[Table 1]
Figure 0004644391
[0019]
[Example 3 and Example 4] Moisturizing gel In the formulation shown in Table 2, the aqueous phase component of A is mixed, heated and dissolved to 80 to 85 ° C. On the other hand, the C component is mixed and dissolved by heating to 80 to 85 ° C., and the B component which is mixed and heated and dissolved in advance to 80 to 85 ° C. is added to be uniform. The aqueous phase component is gradually added to the oil phase component while stirring to uniformly emulsify, and after cooling, the D component is added at 50 ° C. and further cooled to 35 ° C.
[0020]
[Table 2]
Figure 0004644391
[0021]
[Examples 5 and 6] Moisturizing emulsion In the formulation shown in Table 3, the aqueous phase component A is mixed, heated and dissolved to 80 to 85 ° C. On the other hand, the C component is mixed and dissolved by heating to 80 to 85 ° C., and the B component which is mixed and heated and dissolved in advance to 80 to 85 ° C. is added to be uniform. The aqueous phase component is gradually added to the oil phase component while stirring to uniformly emulsify, and after cooling, D component and E component are added at 50 ° C., and further cooled to 35 ° C.
[0022]
[Table 3]
Figure 0004644391
[0023]
[Example 7, Example 8] Moisturizing gel In the formulation shown in Table 4, component A is mixed and dissolved to 80 to 85 ° C. To this, B component and C component which were mixed, heated and dissolved in advance to 80 to 85 ° C. are added, mixed, homogenized, and cooled. Next, the D component is mixed and gradually added thereto, and after stirring and mixing to form a gel, the E component is added and mixed.
[0024]
[Table 4]
Figure 0004644391
[0025]
About the Example of the said invention, formulation stability, skin moisturizing effect, and skin protective effect were evaluated. In that case, as shown in Table 5 in each Example, it replaced with the containing component, and was set as Comparative Example 1-Comparative Example 8, respectively, and used for the test simultaneously.
[0026]
[Table 5]
Figure 0004644391
[0027]
Regarding formulation stability, each of the examples and comparative examples was stored at 25 ° C. for 6 months, and the presence or absence of state changes such as precipitation, separation, aggregation, and phase separation of the contained components was observed, and these state changes were completely observed. The case where it was not observed was indicated as ◯, the case where it was slightly observed as Δ, and the case where it was noticed as ×. Moreover, the skin moisturizing effect and the skin protective effect were evaluated by conducting a use test in which 20 female panelists exhibiting remarkable rough skin symptoms were used as one group. That is, each of the examples and comparative examples was used blindly in each group twice a day for 2 months, and the stratum corneum moisture content was measured before and after the end of the use test and the skin condition was observed. . The stratum corneum water content was expressed as a conductance value on the skin surface by measuring the high-frequency electrical conductivity (conductance) of the skin surface. On the other hand, the skin condition was evaluated and scored according to the evaluation criteria shown in Table 6, and the average value of 20 people was calculated. These results are summarized in Table 7.
[0028]
[Table 6]
Figure 0004644391
[0029]
[Table 7]
Figure 0004644391
[0030]
As is apparent from Table 7, all the examples of the present invention showed good formulation stability, and in the use test, the skin stratum corneum moisture content was clearly improved in all groups, and the skin condition was also improved. It was improved to almost good condition.
[0031]
On the other hand, in Comparative Example 4 in which N-stearoylphytosphingosine was replaced with squalane and Comparative Example 7 in which N-palmitoylphytosphingosine was replaced with 16-methylheptadecanoic acid, a decrease in formulation stability was observed. It was. In addition, although the skin stratum corneum moisture content and skin condition after the end of the use test were improved and improved in the comparative example use group, the degree was smaller than the corresponding example use group. It was.
[0032]
In addition, about Example 1-Example 8 of this invention, the skin irritation reaction which becomes a problem was not seen in the 48-hour back obstruction sticking test which made 30 male panelists into 1 group.
[0033]
【The invention's effect】
As described above in detail, according to the present invention, the solubility of ceramide is good and the preparation stability is excellent, and the percutaneous absorption of ceramide is also good, and the skin stratum corneum barrier function can be effectively improved, which is excellent. An external skin preparation capable of exhibiting a skin moisturizing effect and protective effect could be obtained.
[0034]
Therefore, by using the external preparation for skin according to the present invention, skin aging symptoms such as fine lines and rough skin can be effectively prevented and improved.

Claims (4)

II型セラミド及びIII型セラミドの混合物と、炭素数16〜18の分岐鎖を有する脂肪酸,グリセリルモノオレイルエーテルより選択した1種又は2種以上を含有して成る、皮膚外用剤。A skin external preparation comprising a mixture of type II ceramide and type III ceramide, one or more selected from fatty acids having a branched chain having 16 to 18 carbon atoms and glyceryl monooleyl ether. II型セラミドが、N-アシルジヒドロスフィンゴシンであることを特徴とする、請求項1に記載の皮膚外用剤。The external preparation for skin according to claim 1, wherein the type II ceramide is N-acyl dihydrosphingosine. III型セラミドが、N-アシルフィトスフィンゴシンであることを特徴とする、請求項1又は請求項2に記載の皮膚外用剤。The external preparation for skin according to claim 1 or 2, wherein the type III ceramide is N-acylphytosphingosine. 炭素数16〜18の分岐鎖を有する脂肪酸が、14-メチルペンタデカン酸、16-メチルヘプタデカン酸、2-ヘプチルウンデカン酸及び式(1)で示される2-イソヘプチルイソウンデカン酸より選択されることを特徴とする、請求項1〜請求項3のいずれかに記載の皮膚外用剤。
Figure 0004644391
The fatty acid having a branched chain having 16 to 18 carbon atoms is selected from 14-methylpentadecanoic acid, 16-methylheptadecanoic acid, 2-heptylundecanoic acid and 2-isoheptylisoundecanoic acid represented by the formula (1) The skin external preparation in any one of Claims 1-3 characterized by the above-mentioned.
Figure 0004644391
JP2001197282A 2001-06-28 2001-06-28 Skin preparation Expired - Fee Related JP4644391B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001197282A JP4644391B2 (en) 2001-06-28 2001-06-28 Skin preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001197282A JP4644391B2 (en) 2001-06-28 2001-06-28 Skin preparation

Publications (2)

Publication Number Publication Date
JP2003012486A JP2003012486A (en) 2003-01-15
JP4644391B2 true JP4644391B2 (en) 2011-03-02

Family

ID=19034913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001197282A Expired - Fee Related JP4644391B2 (en) 2001-06-28 2001-06-28 Skin preparation

Country Status (1)

Country Link
JP (1) JP4644391B2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5342736B2 (en) * 2005-04-06 2013-11-13 花王株式会社 Oil-in-water emulsion and method for producing the same
JP4778256B2 (en) * 2005-04-06 2011-09-21 花王株式会社 Oil-in-water emulsion and method for producing the same
CA2817729C (en) * 2010-11-19 2016-05-10 The Procter & Gamble Company Compositions and methods for improving the appearance of facial pores
CA2817974C (en) * 2010-11-19 2017-02-14 Tomohiro Hakozaki Compositions and methods for improving the appearance of facial texture
CN103732206B (en) * 2011-08-09 2015-12-02 花王株式会社 Emulsification composition
EP2795319B1 (en) 2011-12-20 2017-11-29 The Procter and Gamble Company Human skin sample methods and models for assessing tone-specific benefits of agents
JP5900956B2 (en) * 2012-03-13 2016-04-06 株式会社ツツミプランニング Method for producing gel-like cleaning material
US9433567B2 (en) 2013-10-17 2016-09-06 Kao Corporation Skin cosmetic composition
JP6356457B2 (en) * 2014-03-28 2018-07-11 小林製薬株式会社 Ceramide-containing external preparation composition
US9820925B2 (en) 2014-05-30 2017-11-21 Kao Corporation Skin cosmetic
JP2016088872A (en) * 2014-10-31 2016-05-23 株式会社コスモステクニカルセンター TEXTURE IMPROVING AGENT IN WHICH α GEL-STRUCTURE IS FORMED, AND COSMETIC OR EXTERNAL SKIN PREPARATION FOR IMPROVING TEXTURE CONTAINING THE SAME

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114629A (en) * 1999-10-07 2001-04-24 L'oreal Sa Composition for cosmetic containing at least one kind of cationic surfactant, liquid fatty alcohol and ceramide type compound and method using the composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114629A (en) * 1999-10-07 2001-04-24 L'oreal Sa Composition for cosmetic containing at least one kind of cationic surfactant, liquid fatty alcohol and ceramide type compound and method using the composition

Also Published As

Publication number Publication date
JP2003012486A (en) 2003-01-15

Similar Documents

Publication Publication Date Title
US6120779A (en) Use of partial and complete salts of choline and carboxylic acids for the treatment of skin disorders
JP2711549B2 (en) Composition for preventing and improving white hair
HU215488B (en) Method for Solubilizing Salicylic Acid Derivatives, Cosmetic and / or Dermatological Preparations Containing Solubilized Derivatives, and Their Use
JP2010105980A (en) Cosmetic product containing kudzu starch
JP4644391B2 (en) Skin preparation
EP3479815A1 (en) Conditioning agent and conditioning composition
JPH03223206A (en) Cosmetic
JPH11158055A (en) Skin lotion
JPS61260008A (en) Cosmetic composition
CA2365660A1 (en) Treatment for skin
JP3426436B2 (en) Skin cosmetics
JPS63192704A (en) Cosmetic
JP2023553098A (en) Cosmetic composition containing sucrose ester and solvent
JPH0574566B2 (en)
JP3105345B2 (en) Cosmetics
JP3568983B2 (en) Hair restorer
JP2836772B2 (en) Cosmetics
JP2565516B2 (en) Topical skin
JP3439871B2 (en) Cosmetics
JP3481775B2 (en) Microemulsions and cosmetics containing them
JP2000344697A (en) Long-chain branched alcohol, cosmetic and external preparation using the same
JPS62413A (en) Cosmetic
JP2871764B2 (en) Cosmetics
JP3382146B2 (en) External preparation for skin
JP2000327537A (en) Hair grower and cosmetic for hair

Legal Events

Date Code Title Description
RD05 Notification of revocation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7425

Effective date: 20070530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101206

R150 Certificate of patent or registration of utility model

Ref document number: 4644391

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees